Pharvaris to Participate in BofA Securities 2022 Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), has announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas from May 10-12, 2022. The company's presentation is scheduled for May 12, 2022, at 10:00 AM PDT (7:00 PM CEST). A live webcast will be accessible on its website, with a replay available for 30 days post-event.
Details
News Market Reaction – PHVS
The recorded move for PHVS in the trading session of this news was -1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will present at the BofA Securities 2022 Healthcare Conference taking place in Las Vegas, NV from May 10 – 12, 2022.
Pharvaris’ presentation will take place at 10:00 AM PDT (7:00 PM CEST) on Thursday, May 12, 2022. A live webcast of the presentation will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.
About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
Contacts
Pharvaris
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com
+1-617-710-7305
Investors
Sarah McCabe
sarah.mccabe@sternir.com
+1-212-362-1200
Media
Scott Stachowiak, Russo Partners, LLC
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.